solute carrier family 7 member 10Genealiases: ASC1 · HASC-1 · asc-1
Q-omics provides the consensus-scored SLC7A10 profile across patient tissues and cancer cell-line models. SLC7A10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SLC7A10 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SLC7A10 protein abundance shows 17,276 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, KIRC, and GBM as cancer lineages where SLC7A10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC7A10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC7A10 survival associations across molecular data types. SLC7A10 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC7A10 RNA expression–survival associations across cancer types. High SLC7A10 expression shows unfavorable associations in UCEC, CESC and BLCA, but favorable associations in KICH, LUAD and THCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SLC7A10 RNA expression.
This table summarizes SLC7A10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC7A10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC7A10 shows lower tumor expression in KIRC, BRCA, KIRP, HNSC and KICH and higher tumor expression in LUAD. The KIRC box plot shows higher SLC7A10 RNA expression in normal versus tumor tissue (log2 FC = −0.474, t-test p < 0.001).
This table shows molecular features associated with SLC7A10 in patient tissues and cancer cell lines. In patient samples, SLC7A10 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC7A10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
